Introducing Revvity – Expanding the boundaries of human potential through science.
All products and services previously affiliated with Oxford Immunotec are now part of Revvity.

Study Results Confirm T-SPOT®.TB Is Cost-Effective In TB Control Programmes

Oxford, UK; 9th October 2007 – Oxford Immunotec Ltd., the T cell measurement company, today announced the publication of a recent study demonstrating that T-SPOT.TB is cost-effective when used in contact tracing investigation.

In this study taken from the European Respiratory Journal, actual data obtained from the Lausanne University Medical Polyclinic was used in a Markov model to calculate the cost-effectiveness of different screening strategies used for contact tracing.

Three models were compared; Tuberculin Skin Test (TST) alone, T-SPOT.TB alone and a two step approach in which those that were positive by the TST were then given a T-SPOT.TB test. The most cost-effective was the T-SPOT.TB alone.

The study shows that T-SPOT.TB based screening is cost-effective compared to doing no screening or running TST based programs. Also the use of T-SPOT.TB, either alone or in combination with TST, greatly reduces the number of contacts treated to prevent one TB case.

Commenting on the results, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “This study highlights the effectiveness of T-SPOT.TB when used in TB control programmes. Not only does the test identify infected subjects more accurately than existing tests, it also does this in a cost-effective manner. This study will provide further evidence for the use of T-SPOT.TB in contact tracing which will allow the test to become a cornerstone of future Guidelines for TB control.”